The progressive nature of insulin secretory failure makes T2DM patients require insulin therapy to achieve their glycemic goals1, but intensifying insulin therapy increases the risk of hypoglycemia and weight gain2. This evidence concerns the gene INS and type 2 diabetes mellitus.